目的 探讨西格列汀二甲双胍片（Ⅱ）治疗2型糖尿病的临床疗效。方法 选取2016年9月—2017年4月绵阳市中医医院收治的70例2型糖尿病患者为研究对象，随机分为对照组和治疗组，每组各35例。对照组患者口服盐酸二甲双胍片，0.5 g/次，3次/d。治疗组患者口服西格列汀二甲双胍片（Ⅱ），1片/次，2次/d。两组患者均连续治疗12周。观察两组的临床疗效，比较两组的血糖指标、血脂指标、血清脂联素（ADP）、衔接蛋白酶活化因子1（APAF1）、胱抑素C（CysC）水平和淋巴细胞亚群比较。结果 治疗后，对照组和治疗组的总有效率分别为85.71%、94.29%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者的空腹血糖（FPG）、餐后2 h血糖（2 h PBG）、糖化血红蛋白（HbA1c）均较治疗前明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组血糖指标明显低于对照组，两组比较差异有统计学意义（P<0.05）。两组患者的TC、TG、LDL-C水平均较治疗前明显降低，HDL-C显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组的血脂指标优于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者血清ADP、APAF1、CysC水平均较治疗前明显降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组患者ADP、APAF1、CysC水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者CD⁴⁺、CD⁴⁺/CD⁸⁺水平降低，CD⁸⁺水平升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组CD⁴⁺、CD⁸⁺和CD⁴⁺/CD⁸⁺水平明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 磷酸西格列汀二甲双胍（Ⅱ）治疗2型糖尿病具有较好的临床疗效，可改善血糖、血脂指标，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Sitagliptin Metformin Tablets (Ⅱ) in treatment of type 2 diabetes. Methods Patients (70 cases) with type 2 diabetes in Mianyang Hospital of TCM from September 2016 to April 2017 were randomly divided into control group and treatment group, and each group had 35 cases. Patients in the control group were po administered with Metformin Hydrochloride Tablets, 0.5 g/time, three times daily. Patients in the treatment group were po administered with Sitagliptin Metformin Tablets (Ⅱ), 1 tablet/time, twice daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and blood sugar indexes, blood lipid indexes, ADP, APAF1, CysC levels, and lymphocyte subsets in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 85.71% and 94.29%, respectively, and there was difference between two groups (P < 0.05). After treatment, FPG, 2 h PBG, and HbA1c in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the blood sugar indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). TC, TG, and LDL-C in two groups were significantly decreased, but HDL-C was significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the blood lipid indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of ADP, APAF1, and CysC in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And those indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). The levels of CD⁴⁺ and CD⁴⁺/CD⁸⁺ in two groups were significantly increased, but the level of CD⁸⁺ in two groups was significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Sitagliptin Metformin Tablets (Ⅱ) has good effect in treatment of type 2 diabetes, and can improve blood sugarand blood lipid indexes, which has a certain clinical application value.